MedWatch

Experiences from Covid-19 will create success for Demant's virtual product launch

It's unfortunate for hearing aid company Demant that the launch of the firm's new flagship manufacturer coincides with the greatest crisis in the history of the industry. But experiences based on the last nine months in Covid-19 alertness cause CEO Søren Nielsen to trust in a successful launch.

Photo: Niels Hougaard/ERH

Since March, when the Covid-19 crisis started, hearing firm Demant has undergone a significant transitional process, where almost all work procedures in the C25 company have been subjected to a 'new normal' with virtual work processes becoming standard rather than physical meetings and face-to-face interactions.

Demant's recent transition leads the President and CEO Søren Nielsen to strongly believe that the firm's new flagship product, the hearing aid Oticon More, will be successful. It replaces its predecessor, the blockbuster Oticon Opn S.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs